Trigeminal neuralgia (TN) is a debilitating pain disorder characterized by recurrent, paroxysmal facial pain along the distribution of the trigeminal nerve and its branches. Despite its relatively low prevalence, TN significantly impairs the quality of life of affected individuals. This review provides a comprehensive overview of the pathophysiology, clinical presentation, diagnostic criteria, and management strategies for trigeminal neuralgia based on current evidence and clinical expertise.

Introduction: Trigeminal neuralgia is a chronic pain syndrome affecting the trigeminal nerve and its branches, typically manifesting as sudden, severe facial pain. Understanding the underlying mechanisms driving trigeminal neuralgia is essential for accurate diagnosis and effective management.

Epidemiology: Trigeminal neuralgia is relatively rare, with an estimated prevalence of 4 to 13 per 100,000 individuals. It most commonly affects individuals over the age of 50, although cases can occur at any age. Women are more frequently affected than men, and there is an increased prevalence in patients with multiple sclerosis.

Pathophysiology: The pathophysiology of trigeminal neuralgia involves neurovascular compression at the root entry zone of the trigeminal nerve, leading to demyelination and ectopic firing of nociceptive fibers. Vascular loops, most commonly the superior cerebellar artery, impinge on the trigeminal nerve, causing episodes of lancinating pain. Neuroinflammatory processes and central sensitization may also contribute to the maintenance of pain in some cases.

Clinical Presentation: Trigeminal neuralgia is characterized by unilateral, electric shock-like or stabbing pain along the distribution of one or more branches of the trigeminal nerve. The pain is typically triggered by innocuous stimuli such as light touch, chewing, or talking and can last from seconds to minutes. Patients may experience periods of remission followed by recurrent bouts of pain, leading to significant functional impairment and emotional distress.

Diagnosis: The diagnosis of trigeminal neuralgia is primarily based on clinical history and examination. Neuroimaging studies such as magnetic resonance imaging (MRI) may be indicated to rule out structural lesions or vascular abnormalities, particularly in atypical presentations or refractory cases. The International Classification of Headache Disorders (ICHD) provides diagnostic criteria for TN.

Management: Management of trigeminal neuralgia aims to alleviate pain, improve quality of life, and minimize adverse effects of treatment. First-line pharmacotherapy includes anticonvulsants such as carbamazepine and oxcarbazepine, which are effective in reducing pain frequency and intensity in the majority of patients. For refractory cases, surgical interventions such as microvascular decompression, stereotactic radiosurgery, and percutaneous ablative procedures may be considered. Non-pharmacological modalities including acupuncture, cognitive-behavioral therapy, and neuromodulation techniques can complement pharmacotherapy in comprehensive pain management.

Conclusion: Trigeminal neuralgia is a debilitating pain disorder characterized by paroxysmal facial pain along the distribution of the trigeminal nerve and its branches, significantly impacting the quality of life of affected individuals. Accurate diagnosis and appropriate management are essential for optimizing patient outcomes and relieving suffering. Further research is needed to elucidate the underlying pathophysiological mechanisms and develop targeted therapeutic interventions for trigeminal neuralgia. Collaboration between neurologists, pain specialists, and neurosurgeons is crucial for comprehensive management and patient-centered care.